Pharmacokinetics of Recombinant and Urinary Human Chorionic Gonadotrophin
Pharmacokinetics of recombinant (r-hCG) versus urinary (u-hCG) human chorionic gonadotrophin with an emphasis on profiling effect of the WADA's anti doping tests.
Sydney Local Health District
10 participants
May 3, 2022
Interventional
Conditions
Summary
This research study will evaluate and update the efficiency of an old and new form of test to detect hCG in blood for an antidoping setting.
Eligibility
Inclusion Criteria1
- Healthy males over the age of 18
Exclusion Criteria4
- History of any chronic disease or condition requiring regular medical management
- History of male infertility or pituitary-testicular dysfunction
- History of androgen (anabolic steroid) use or abuse
- Allergic or other severe adverse reaction to hCG injections or their ingredients
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Single dose of Recombinant human Chorionic Gonadotrophin (250 micrograms, r-hCG, Ovidrel, MerckSerono, Australia, ARTG 96037) and Urinary human chorionic gonadotrophin (5000 IU, u-hCG, Pregnyl, Merck/Schering Plough/Organon, Australia; ARTG 14518). Two phase cross over open and unblinded treatment. Subcutaneous injections are given by trained registered nurses in a hospital setting. The drugs are given at 2 week intervals without a specific washout period but the drug effects lasts about a week (varies betwene individuals) and is not critical in this study. Just need samples from men exposed to both
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12621001053819